2020
DOI: 10.1016/j.jgo.2019.09.011
|View full text |Cite
|
Sign up to set email alerts
|

Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
6
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(7 citation statements)
references
References 23 publications
(42 reference statements)
1
6
0
Order By: Relevance
“…A larger study of 245 patients found no increased risk of toxicity with age, although patients age >80 years had substantially lower overall survival (median 3.6 months) compared to those age 70 to 79 years (median 12.9 months) (81). Additional observational evidence found no new safety signals in older patients receiving ICI therapy (82,83). Furthermore, two meta-analyses of ICI clinical trials found that patients age ≥65 years derive similar clinical benefit to younger patients, and actually may have a lower incidence of grade 3 and 4 irAE (84,85).…”
Section: Renalmentioning
confidence: 96%
“…A larger study of 245 patients found no increased risk of toxicity with age, although patients age >80 years had substantially lower overall survival (median 3.6 months) compared to those age 70 to 79 years (median 12.9 months) (81). Additional observational evidence found no new safety signals in older patients receiving ICI therapy (82,83). Furthermore, two meta-analyses of ICI clinical trials found that patients age ≥65 years derive similar clinical benefit to younger patients, and actually may have a lower incidence of grade 3 and 4 irAE (84,85).…”
Section: Renalmentioning
confidence: 96%
“…Discontinuation rates due to treatment-related AEs were low irrespective of age (4–5%) [ 24 ]. However, a retrospective analysis of 324 Belgian patients with NSCLC showed no significant difference between older (≥70) and younger (<70 years) patients in terms of PFS (4 months versus 3.7 months, p = 0.483) and OS (9.3 months versus 8.4 months, p = 0.638) [ 25 ]. The incidence of AEs of all grades and of grade 3–4 AEs was also similar between age groups [ 25 ].…”
Section: Nivolumab In Daily Practicementioning
confidence: 99%
“…However, a retrospective analysis of 324 Belgian patients with NSCLC showed no significant difference between older (≥70) and younger (<70 years) patients in terms of PFS (4 months versus 3.7 months, p = 0.483) and OS (9.3 months versus 8.4 months, p = 0.638) [ 25 ]. The incidence of AEs of all grades and of grade 3–4 AEs was also similar between age groups [ 25 ]. Similarly, in a group of Italian patients with non-squamous NSCLC, 522 of 1588 patients were over 70 years of age; these patients reached a median OS of 11.5 months (95% CI 10.0–13.0), while for the 232 patients aged over 75 years OS was 12.0 months (95% CI 9.2–14.8) [ 6 ].…”
Section: Nivolumab In Daily Practicementioning
confidence: 99%
“…Joris et al [22] conducted a Belgian RWD cohort, achieving promising results with Nivolumab in patients aged ≥70 years. Efficacy data of the 108 older patients included was favorable, with a nonsignificant trend towards improved PFS compared with the younger subgroup (4.0 months, CI 1.0-7-0 vs 3.7 months, CI 2.6-4.8, p = 0.48).…”
Section: Discussionmentioning
confidence: 99%